Aurinia Pharmaceuticals Inc. 8-K

What Happened
Aurinia Pharmaceuticals Inc. announced its financial results for the quarter ended March 31, 2026 in a press release dated May 7, 2026. The press release is attached to the company’s Form 8-K as Exhibit 99.1 and was furnished under Item 2.02 (Results of Operations and Financial Condition). The filing also includes the Inline XBRL cover page (Exhibit 104). The report was signed by Michael Hearne, Chief Financial Officer, on May 7, 2026.

Key Details

• Press release with quarter-ended March 31, 2026 results attached as Exhibit 99.1 to the Form 8-K (filed/furnished May 7, 2026).
• Filing cites Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
• Inline XBRL cover page included as Exhibit 104.
• Form 8-K signed by Michael Hearne, CFO, on May 7, 2026.

Why It Matters
This filing notifies investors that Aurinia’s latest quarterly earnings and related financial information are available. Retail investors should read the attached press release (Exhibit 99.1) for revenue, expenses, cash position, and any management commentary or guidance that could affect the stock. The 8-K itself furnishes the release and the XBRL data file, so review the exhibits or the company’s investor relations/SEC page for the full financial details.